Summary
Abbott Laboratories (ABT) announced the entry into a new Five Year Credit Agreement on November 29, 2018, replacing its previous credit facility. This new agreement provides the company with access to a $5 billion unsecured revolving credit line. Importantly, there were no outstanding borrowings under either the new or the terminated existing agreement at the time of the filing. The termination of the prior credit agreement, dated July 10, 2014, was a procedural step executed concurrently with the establishment of the new facility. The new agreement features similar terms to the old one, including interest rates tied to base or Eurodollar rates plus an applicable margin, and standard covenants and events of default. This action demonstrates Abbott's proactive approach to managing its liquidity and financial flexibility.
Key Highlights
- 1Abbott Laboratories entered into a new $5 billion unsecured Five Year Credit Agreement.
- 2The new credit facility became effective on November 29, 2018.
- 3The agreement provides significant borrowing capacity to support ongoing operations and strategic initiatives.
- 4There were no outstanding borrowings under the new credit agreement at the time of filing.
- 5The new agreement replaced a previous Five Year Credit Agreement dated July 10, 2014.
- 6The previous credit agreement also had a $5 billion unsecured revolving credit line.
- 7No borrowings were outstanding under the previous agreement prior to its termination.